Clinical Trials Browser

Phase 2 × Fulvestrant × Thoracic × Clear all

Carcinoma, Non-Small-Cell Lung

NCT04553133 2026-04-13

PF-07104091 as a Single Agent and in Combination Therapy

Phase 2 Active not recruiting

157 enrolled

BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Phase 2 Active not recruiting

217 enrolled 19 charts

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT04557449 2025-10-01

CDK4i

Phase 2 Active not recruiting

362 enrolled

BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT01953926 2024-03-12

SUMMIT

Phase 2 Terminated

582 enrolled 27 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT01556191 2021-01-08

LADIE

Phase 2 Completed

379 enrolled

Thoracic

Lung Neoplasms

NCT00100854 2019-03-05

Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

108 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00932152 2017-10-19

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

Phase 2 Terminated

3 enrolled 6 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00592007 2017-06-06

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Phase 2 Terminated

7 enrolled 3 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

KAT6

PF-07104091 as a Single Agent and in Combination Therapy

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

CDK4i

SUMMIT

LADIE

Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer